Turkish experience in rheumatoid arthritis patients with clinical apparent amyloid deposition

References

• Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2008;18:109–18
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 2007;25:518–22
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24
   PubMed Web of Science ®Google Scholar
• Younes M, Korbaa W, Moussa A, Zrour S, Bejia I, Touzi M, Zakhama A, et al. Prevalence of subclinical amyloidosis in Tunisian patients with rheumatoid arthritis. Joint Bone Spine 2009;76:254–9
   PubMedGoogle Scholar
• Kuroda T, Wada Y, Kobayashi D, Murakami S, Sakai T, Hirose S, Tanabe N, et al. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 2009;36:2409–15
   PubMed Web of Science ®Google Scholar
• Carmona L, González-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmartí R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003;62:897–900
   PubMed Web of Science ®Google Scholar
• Wakhlu A, Krisnani N, Hissaria P, Aggarwal A, Misra R. Prevalence of secondary amyloidosis in Asian North Indian patients with rheumatoid arthritis. J Rheumatol 2003;30:948–51
   PubMed Web of Science ®Google Scholar
• Hazenberg BP, van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis 2000;59:577–9
   PubMed Web of Science ®Google Scholar
• Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford) 1999;38:499–503
   PubMed Web of Science ®Google Scholar
• Imeryuz N, Yazici H, Kocak H, Erk M, Ozder A, Karcier SM, Ozkan M, et al. Pericardial and pulmonary involvement in rheumatoid arthritis in Turkey. Clin Rheumatol 1994;13:239–43
   PubMedGoogle Scholar
• Immonen K, Finne P, Grönhagen-Riska C, Pettersson T, Klaukka T, Kautiainen H, Hakala M. A marked decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases – data from nationwide registries in Finland. Amyloid 2011;18:25–8
   PubMed Web of Science ®Google Scholar
• Vasala M, Immonen K, Kautiainen H, Hakala M. More evidence of declining incidence of amyloidosis associated with inflammatory rheumatic diseases. Scand J Rheumatol 2010;39:461–5
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361–71
   PubMed Web of Science ®Google Scholar
• Maury CP, Teppo AM. Mechanism of reduced amyloid-A-degrading activity in serum of patients with secondary amyloidosis. Lancet 1982;2:234–7
   PubMedGoogle Scholar
• Falck HM, Maury CPJ, Teppo AM, Wegelius O. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. Br Med J 1983;286:1391–3
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MP, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in relation to the circulating concentration of serum amyloid A protein. Lancet 2001;358:24–9
   PubMed Web of Science ®Google Scholar
• Maury CP, Teppo AM, Wafin F, Wegelius O, Friman C, Koskimies S. Class-specific rheumatoid factors, DR antigens, and amyloidosis in patients with rheumatoid arthritis. Ann Rheum Dis 1988;47:546–52
   PubMedGoogle Scholar
• Maury CP, Liljeström M, Tiitinen S, Laiho K, Kaarela K, Ehnholm C. Apolipoprotein E phenotypes in rheumatoid arthritis with or without amyloidosis. Amyloid 2001;8:270–3
   PubMed Web of Science ®Google Scholar
• Kuroda T, Otaki Y, Sato H, Fujimura T, Nakatsue T, Murakami S, Sakatsume M, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. Rheumatol Int 2008;28:1155–9
   PubMed Web of Science ®Google Scholar
• Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571–3
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2010;29:1395–401
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 2003;48:2019–24
   PubMed Web of Science ®Google Scholar
• Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, Portales RG, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005;118:552–6
   PubMed Web of Science ®Google Scholar
• Fernandez-Nebro A, Olive A, Castro MC, Varela AH, Riera E, Irigoyen MV, García de Yébenes MJ, et al. Long-term TNF-alpha blockade in patients with amyloid AA amyloidosis complicating rheumatic diseases. Am J Med 2010;123:454–61
   PubMed Web of Science ®Google Scholar
• Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: longterm followup with special reference to amyloidosis. J Rheumatol 1999;26:898–903
   PubMed Web of Science ®Google Scholar
• Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford) 2011;40:821–5
   Google Scholar
• Narváez J, Hernández MV, Ruiz JM, Vaquero CG, Juanola X, Nollaa JM. Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis. Joint Bone Spine 2011;78:101–3
   PubMed Web of Science ®Google Scholar